HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, announced it has released a new HTG EdgeSeq Mouse mRNA Tumor Response Panel available now in the United States and Europe.
The HTG EdgeSeq Mouse mRNA Tumor Response Panel is designed for use in mouse oncology models to identify and quantify expression of genes and gene pathways from a variety of sample types, including formalin-fixed, paraffin-embedded (FFPE) tissue. The HTG EdgeSeq Mouse mRNA Tumor Response Panel is designed to measure over 1,600 mouse mRNA targets in one RNA extraction-free assay.
“We are pleased with the rate of adoption of our portfolio of HTG EdgeSeq human gene expression assays in biomarker development projects,” stated John Lubniewski, HTG’s President and Chief Operating Officer. “The expansion of our assay portfolio to mouse oncology models meets a customer need for profiling earlier in the biomarker discovery process where a high volume of testing is done. Ultimately, we believe the addition of mouse profiling will enable customers to carry forward from discovery to the patient without changing platforms,” Mr. Lubniewski concluded.
